Long-acting injectable drug developer for urology, oncology, and endocrinology
Tolmar manufactures specialty pharmaceuticals with expertise in long-acting injectable formulations across three therapeutic areas. The hiring velocity is accelerating, with manufacturing roles dominating the open pipeline (42 of 107 active positions)—a ratio that reflects operational scaling rather than R&D expansion. Pain-point clustering around aseptic manufacturing yield, regulatory compliance, and inventory management suggests the company is optimizing production throughput while managing the complexity of injectable drug manufacturing.
Tolmar is a specialty pharmaceutical manufacturer founded in 2007, headquartered in Fort Collins, Colorado. The company develops treatments in urology, oncology, and pediatric endocrinology, with particular strength in long-acting injectable drug delivery. The organization operates across 1,001–5,000 employees and is actively hiring across manufacturing, sales, engineering, research, and operations—with most growth centered in manufacturing and field sales roles. Tolmar serves patient and provider communities, positioning itself as a partner to healthcare systems and medical professionals rather than a direct-to-consumer brand.
Long-acting injectable drug delivery across urology, oncology, and pediatric endocrinology. The company is known internationally for advanced capabilities in injectable formulation and aseptic manufacturing processes.
Regulatory compliance, aseptic manufacturing yield improvement, process variability reduction, and inventory management system implementation. The company is also working to meet product release schedules and explore automation opportunities.
Other companies in the same industry, closest in size